Pfizer Corporation

Sugen Incorporated

Pfizer Products Inc.

Dart Neuroscience, LLC

Iambic Therapeutics, Inc.

Iriny Botrous

Jingrong Jean Cui

Min Teng

Jennifer R Zhang

Brian Dyck

Yufeng Hong

Seiji Nukui

Brett C Bookser

Aaron Craig Burns

Cathleen Elizabeth Hanau

Hui Li

Lei Jia

Pei-Pei Kung

G Davis Harris, Jr

Michael I Weinhouse

Joe Anh Tran

Nicholas Brian Raffaele

Dilip Ramakant Bhumralkar

Mitchell David Nambu

Mason Alan Pairish

Chunfeng Yin

Hong Shen

Fang-Jie Zhang

Michelle Bich Tran-Dube

Jerry Jialun Meng

Eileen Valenzuela Tompkins

Lee Andrew Funk

Stephen A Kolodziej

DeMichael Chung

Margaret McCarrick

Ji Yu Chu

Kevin Kun-Chin Liu

Dange Vijay Kumar

Andrew Kleinke

Joanne Johnson

Christopher G Nelson

Jason (Qishen) Lin

Xiaoyuan (Sharon) Li

Allison Walter

Laurent Gomez

Svitlana Kulyk

G Davis Harris

Shawn Wright

Wallace Derricotte

Joseph Dennis

Jingjong Jean Cui

G Davis Harris Jr

Jason Lin

Dilip Bhumralkar

Margaret Mccarrick

Michael Weinhouse

Joe Tran

Demichael Chung

Xiaoyuan(sharon) Li

Jason(qishen) Lin

Compounds and methods for modulating HER2

Substituted furanopyrimidine chemical entities of Formula (I): wherein Rhas any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.

Substituted furanopyrimidine compounds as PDE1 inhibitors

Substituted furanopyrimidine chemical entities of Formula (I): wherein Rhas any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders. 

The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R, R, R, R, R, R, R, and Rare as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.

[object Object]

The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R, R, R, R, R, R, R, and Rare as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ. 

3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives

Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET. 

Aminoheteroaryl compounds as protein kinase inhibitors

The present invention relates to compounds of the Formulae (I)-(IV), wherein R-R, R-R, X and Y are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer 

Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors

Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET 

Growing community of inventors

San Diego, CA, United States of America

Iriny Botrous